About Us

Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome.  Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.  

Read more



November 27, 2015

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015

Read more
November 25, 2015

Revive Therapeutics Announces Listing on the OTCQB Market Exchange

Read more
November 18, 2015

Dr. Lee S. Simon Joins Revive Therapeutics as Senior Clinical and Regulatory Affairs Advisor

Read more
October 26, 2015

Revive Therapeutics Announces US FDA Grants Orphan Drug Designation for Bucillamine for the Treatment of Cystinuria

Read more
October 21, 2015

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2015

Read more
Corporate presentation



Winter 2015